Nyrada Brain Injury Drug Candidates demonstrate delivery via preferred Administration route in Preclinical Pharmacokinetics Study

  • Jul 15, 2020 AEST
  • Team Kalkine

Australian listed drug development company, Nyrada Inc. (ASX: NYR) reported that both the potent drug candidates-NYX-242 and NYX-1010 can be given via preferred route of administration for moderate-severe TBI and stroke patients, with desired pharmacokinetic profiles for clinical studies. 

In the preclinical pharmacokinetic study, both the lead preclinical drug candidates achieved durable therapeutic levels when continuous intravenous administration of the drug candidates was maintained. 

Both compounds, in the uninjured brain of a second animal species, were seen to readily cross the blood-brain-barrier, with no observed adverse effects after continuous dosing for 6 hours. 

Nyrada is currently carrying out the study for testing intranasal drug delivery, which is the preferred route for treatment of mild traumatic brain injury and concussion injury, common in sports. 

NYR traded at $0.215, up 2.4% on 15 July 2020 (12:33 PM AEST).



The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK